{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T01:47:15Z","timestamp":1775094435085,"version":"3.50.1"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T00:00:00Z","timestamp":1712793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Allogeneic hematopoietic stem cell transplant for myeloid neoplasms with increased fibrosis is uncommon; morphologic features posttransplant can be concerning for persistent disease.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this retrospective study, we identified 22 patients transplanted for myeloproliferative neoplasms or chronic myelomonocytic leukemia with fibrosis at our institution, and reviewed slides from pretransplant and posttransplant bone marrow biopsies. Clinical features and results of molecular, chimerism, and cytogenetic studies were retrieved from the medical record.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Pretransplant bone marrow biopsies commonly exhibited hypercellularity, atypical megakaryocytes, and reticulin fibrosis. At day 100, 36% of biopsies had reticulin grade &amp;gt;MF1 and 33% of those tested had positive molecular studies, with no significant associations between day 100 marrow characteristics and molecular profile or peripheral count recovery times. In the 1 year posttransplant biopsies (n = 12), 7 of 9 had negative molecular studies; of these, none had reticulin grade &amp;gt;MF1, 1 had trichrome 1+, 2 had atypical megakaryocytes, and 1 was hypercellular.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Supporting recent literature, our study indicates that persistent day 100 reticulin fibrosis\/collagen deposition does not show an association with day 100 molecular status. Our study additionally provides data for 12 patients with 1 year posttransplant marrow biopsies, with the majority of those lacking either increased fibrosis or molecular evidence of persistent disease.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/labmed\/lmae018","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T16:35:12Z","timestamp":1708014912000},"page":"602-608","source":"Crossref","is-referenced-by-count":3,"title":["Bone marrow findings post allogeneic transplant for myeloproliferative neoplasms and chronic myelomonocytic leukemia with increased fibrosis"],"prefix":"10.1093","volume":"55","author":[{"given":"Srishti","family":"Gupta","sequence":"first","affiliation":[{"name":"University of Virginia School of Medicine and University of Virginia Health System , Charlottesville, VA , US"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth L","family":"Courville","sequence":"additional","affiliation":[{"name":"University of Virginia School of Medicine and University of Virginia Health System , Charlottesville, VA , US"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,4,11]]},"reference":[{"key":"2024090405514464500_CIT0001","first-page":"799","article-title":"Chronic myelomonocytic leukemia with fibrosis is a distinct disease subset with myeloproliferative features and frequent JAK2 p.V617F mutations","volume-title":"Am J Surg Pathol.","author":"Gur","year":"2018"},{"key":"2024090405514464500_CIT0002","first-page":"429","article-title":"Myeloid neoplasms with features intermediate between primary myelofibrosis and chronic myelomonocytic leukemia","volume-title":"Mod Pathol.","author":"Chapman","year":"2018"},{"key":"2024090405514464500_CIT0003","first-page":"290","article-title":"Utility of JAK2 V617F allelic burden in distinguishing chronic myelomonocytic leukemia from primary myelofibrosis with monocytosis","volume-title":"Hum Pathol.","author":"Hu","year":"2019"},{"key":"2024090405514464500_CIT0004","first-page":"801","article-title":"Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management","volume-title":"Am J Hematol.","author":"Tefferi","year":"2023"},{"issue":"8","key":"2024090405514464500_CIT0005","first-page":"1128","article-title":"European consensus on grading bone marrow fibrosis and assessment of cellularity","volume":"90","author":"Thiele","year":"2005","journal-title":"Haematologica."},{"key":"2024090405514464500_CIT0006","first-page":"905","article-title":"Problems and pitfalls in grading of bone marrow fibrosis, collagen deposition and osteosclerosis\u2014a consensus-based study","volume-title":"Histopathology.","author":"Kvasnicka","year":"2016"},{"key":"2024090405514464500_CIT0007","first-page":"4","article-title":"Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists","volume-title":"J Mol Diagn.","author":"Li","year":"2017"},{"key":"2024090405514464500_CIT0008","first-page":"151860","article-title":"Value and pitfalls of assessing bone marrow morphologic findings to predict response in patients with myelofibrosis who undergo hematopoietic stem cell transplantation","volume-title":"Ann Diagn Pathol.","author":"Khanlari","year":"2022"},{"key":"2024090405514464500_CIT0009","first-page":"812","article-title":"Dynamic of bone marrow fibrosis regression predicts survival after allogeneic stem cell transplantation for myelofibrosis","volume-title":"Biol Blood Marrow Transplant.","author":"Kroger","year":"2014"},{"key":"2024090405514464500_CIT0010","first-page":"879","article-title":"Dynamics of bone marrow changes in patients with chronic idiopathic myelofibrosis following allogeneic stem cell transplantation","volume-title":"Histol Histopathol.","author":"Thiele","year":"2005"},{"key":"2024090405514464500_CIT0011","first-page":"4115","article-title":"Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia","volume-title":"Blood.","author":"Rondelli","year":"2005"},{"key":"2024090405514464500_CIT0012","first-page":"1872","article-title":"Resolution of bone marrow fibrosis in a patient receiving JAK1\/JAK2 inhibitor treatment with ruxolitinib","volume-title":"Haematologica.","author":"Wilkins","year":"2013"},{"key":"2024090405514464500_CIT0013","first-page":"1532","article-title":"2021 Update on allogeneic hematopoietic stem cell transplant for myelofibrosis: a review of current data and applications on risk stratification and management","volume-title":"Am J Hematol.","author":"Ali","year":"2021"},{"key":"2024090405514464500_CIT0014","first-page":"932","article-title":"Busulfan- or thiotepa-based conditioning in myelofibrosis: a phase II multicenter randomized study from the GITMO Group","volume-title":"Biol Blood Marrow Transplant.","author":"Patriarca","year":"2019"}],"container-title":["Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/labmed\/article-pdf\/55\/5\/602\/58985554\/lmae018.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/labmed\/article-pdf\/55\/5\/602\/58985554\/lmae018.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T19:30:51Z","timestamp":1725478251000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/labmed\/article\/55\/5\/602\/7644250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,11]]},"references-count":14,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,4,11]]},"published-print":{"date-parts":[[2024,9,4]]}},"URL":"https:\/\/doi.org\/10.1093\/labmed\/lmae018","relation":{},"ISSN":["0007-5027","1943-7730"],"issn-type":[{"value":"0007-5027","type":"print"},{"value":"1943-7730","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,4,11]]}}}